ADVA
12.8.2021 09:02:11 CEST | Business Wire | Press release
ADVA (FSE: ADV) today introduced its FSP 150-XJ128 , the industry’s first Layer 2 demarcation device that offers an easy route to 25Gbit/s connectivity services. The solution is specifically designed to enable enterprise networks to expand in an easy and cost-effective way. Until now, businesses had to choose between juggling their 10Gbit/s devices or making the expensive leap to 100Gbit/s. With the ADVA FSP 150-XJ128, they can address soaring data demand without using complex modulation techniques or undergoing a costly footprint increase. The solution simply slots into existing network infrastructure and delivers 2.5x the bandwidth at a lower cost per bit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005050/en/
“Our FSP 150-XJ128 is the technology that businesses have been calling for. It empowers them to take the natural next step with zero hassle and without unnecessary expense. For many enterprises, trying to manage rapidly rising bandwidth needs using 10Gbit/s demarcation devices has become a real headache. Yet it doesn’t make economic sense to overhaul their entire system and go all the way to 100Gbit/s. What we’re providing is the ideal stepping stone for secure business growth,” said Christoph Glingener, CTO, ADVA. “Until today, there was no middle ground. Now, businesses can slot our FSP 150-XJ128 into their existing network infrastructure and seize new revenue opportunities.”
The ADVA FSP 150-XJ128 is ideal for 5G sites moving to 25Gbit/s and the perfect choice for preparing cable networks for DOCSIS 4.0 and above. The compact device supports 25Gbit/s Ethernet services with sophisticated OAM capabilities. Optimized for cost-sensitive high-bandwidth edge applications, the ADVA FSP 150-XJ128 features fanless operation and an extended temperature range, removing the need for expensive air-conditioning. With its hardware-assisted synchronization features, it also meets the most stringent timing requirements. Managed by ADVA’s Ensemble Controller and Ensemble Packet Director , the FSP 150-XJ128 gives operations teams the power of intuitive and comprehensive network control.
“What we’re offering businesses is a solution that hits the sweet spot. It enables enterprise networks to handle significantly more workloads and data-hungry applications without major investment or increased complexity. Now there’s a way to meet the bandwidth needs of 5G and cloud computing without complex modulation techniques or breaking the bank,” commented Eli Angel, VP, product line management, ADVA. “As we’ve shown in several customer demos, our simple plug-and-play FSP 150-XJ128 delivers 2.5x the bandwidth in an instant. What’s more, it provides the Layer 2 demarcation and synchronization capabilities that enterprise networks require. Today’s launch marks the start of a new era of 25Gbit/s connectivity and a whole new world of opportunity for businesses.”
Further information on the ADVA FSP 150-XJ128 is available in these slides: https://adva.li/fsp-150-xj128-slides .
Additional details can also be found in this video: https://youtu.be/ikE9quU0gjc .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005050/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
